425 filed Sep 9, 2026 at 16:54 ET
InMed Pharmaceuticals filed a Rule 425 communication reporting FY2026 annual results and providing a corporate update on its proposed merger with Mentari Therapeutics. The net loss widened to $12.6M from $8.2M, cash burned to $2.2M, and the company is a pre-revenue shell whose value is entirely tied to the pending reverse-merger into Mentari, which has raised ~$490M in pre-closing financing. The merger remains on track for Q4 2026 close, but InMed's standalone financials show a deteriorating cash position and no operating revenue, making this a binary event on deal completion.